BRIEF—Valneva and HOOKIPA Pharma agree collaboration deal

Vaccine specialist Valneva and HOOKIPA Pharma have agreed on a three-year collaboration and manufacturing deal.

Under the terms of the agreement, Valneva’s Swedish unit will provide analytical services, help scale-up processes and produce GMP clinical trial material for undisclosed fees.

The deal will support HOOKIPA’s Vaxwave and TheraT arenavirus vector technologies, and may be extended.

HOOKIPA chief executive Joern Aldag said: “The collaboration with Valneva will give us access to a dedicated GMP facility and qualified workforce for the manufacture of clinical trial material according to our specific needs.”